Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

HCV treatment cuts liver-related mortality

27 Jul 2020

The survival benefits associated with treating hepatitis C virus (HCV) infections are driven primarily by a reduction in liver-related mortality, a recent study has found.

The study included 50,674 HCV patients who had been treated. Causes of death were retrieved from the national statistics index and were used to calculate liver-related mortality rates. Comparator groups of 31,749 untreated patients with the infection and 73,526 uninfected controls were also included.

During the observation period, 8.6 percent of the treated patients died. This was notably lower than the 35.0-percent mortality rate in their untreated counterparts, and the 14.28-percent rate in the uninfected controls. In these respective groups, the proportions of liver-related deaths were 31.6 percent, 23.3 percent, and 2.6 percent.

Relative to the overall group sizes, however, the proportion of liver-related deaths were 2.72 percent, 8.16 percent, and 0.37 percent, respectively. The resulting incidence rate per 100 patient-years was significantly lower in those who were vs were not treated (0.28 vs 1.44; p<0.0001). Controls likewise saw a lower incidence rate of liver-related mortality than untreated HCV patients (p<0.0001).

Cox proportional hazards regression analysis further confirmed that HCV treatment significantly and strongly reduced the risk of liver-related mortality, even after adjusting for comorbidities and demographic factors (adjusted hazards ratio, 0.25, 95 percent confidence interval, 0.24–0.27).

This effect was even more pronounced when newer direct-acting antivirals were used, rather than pegylated interferon or ribavirin-based regimens.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.